CytomX Therapeutics (STU:6C1) ROE % Adjusted to Book Value : Negative Equity% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics ROE % Adjusted to Book Value?

CytomX Therapeutics's ROE % for the quarter that ended in Sep. 2024 was Negative Equity. CytomX Therapeutics's PB Ratio for the quarter that ended in Sep. 2024 was N/A. CytomX Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 was Negative Equity.

CytomX Therapeutics ROE % Adjusted to Book Value Historical Data

The historical data trend for CytomX Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics ROE % Adjusted to Book Value Chart

CytomX Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-19.93

CytomX Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															Negative Equity	Negative Equity	Negative Equity	-	Negative Equity

Competitive Comparison of CytomX Therapeutics's ROE % Adjusted to Book Value

For the Biotechnology subindustry, CytomX Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytomX Therapeutics's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where CytomX Therapeutics's ROE % Adjusted to Book Value falls into.

CytomX Therapeutics ROE % Adjusted to Book Value Calculation

CytomX Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

CytomX Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	Negative Equity	/	N/A
	=	Negative Equity

CytomX Therapeutics ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics Headlines

No Headlines